Aug. 13 at 12:01 PM
$LGVN If you mean positive as in outstanding or so positive that approval and revenues get very heavily priced in then arguably more like
$25 a share or
$30 or higher would be fair value as it would arguably warrant a billion dollar market cap. Especially considering eventual worldwide revenues in the drug. Plus there is the priority voucher. There would be more dilution of course though they'd get another
$15 million cash if news is good and sp stays above
$1.85 a share I believe as part of the
$30 million financing deal they did in March (
$15 million was already received from it).
More likely it wouldn't be such a slam dunk result though, however considering the MC is so low currently at
$23 million, it may only need "neutral news" that gives say a more chance than not of FDA approval for a much higher sp here. Of course it could also be bad news and sp would of course fall, but to me it seems quite a-symetric risk/reward here.
